Kinase drug discovery 20 years after imatinib: progress and future directions

P Cohen, D Cross, PA Jänne - Nature reviews drug discovery, 2021 - nature.com
Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases

R Rupaimoole, FJ Slack - Nature reviews Drug discovery, 2017 - nature.com
In just over two decades since the discovery of the first microRNA (miRNA), the field of
miRNA biology has expanded considerably. Insights into the roles of miRNAs in …

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

J Hallin, V Bowcut, A Calinisan, DM Briere, L Hargis… - Nature medicine, 2022 - nature.com
Recent progress in targeting KRASG12C has provided both insight and inspiration for
targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and …

[HTML][HTML] Oncogenic signaling pathways in the cancer genome atlas

F Sanchez-Vega, M Mina, J Armenia, WK Chatila… - Cell, 2018 - cell.com
Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co …

Tracking the evolution of non–small-cell lung cancer

M Jamal-Hanjani, GA Wilson… - … England Journal of …, 2017 - Mass Medical Soc
Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective …

Towards a general-purpose foundation model for computational pathology

RJ Chen, T Ding, MY Lu, DFK Williamson, G Jaume… - Nature Medicine, 2024 - nature.com
Quantitative evaluation of tissue images is crucial for computational pathology (CPath) tasks,
requiring the objective characterization of histopathological entities from whole-slide images …

The current state of the art and future trends in RAS-targeted cancer therapies

SR Punekar, V Velcheti, BG Neel… - Nature reviews Clinical …, 2022 - nature.com
Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has
historically been considered 'undruggable'owing to a lack of pharmacologically targetable …

RAS proteins and their regulators in human disease

DK Simanshu, DV Nissley, F McCormick - Cell, 2017 - cell.com
RAS proteins are binary switches, cycling between ON and OFF states during signal
transduction. These switches are normally tightly controlled, but in RAS-related diseases …

[HTML][HTML] The evolution of lung cancer and impact of subclonal selection in TRACERx

AM Frankell, M Dietzen, M Al Bakir, EL Lim, T Karasaki… - Nature, 2023 - nature.com
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …

Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma

MA Gillette, S Satpathy, S Cao, SM Dhanasekaran… - Cell, 2020 - cell.com
To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic
opportunities, we performed comprehensive proteogenomic characterization of 110 tumors …